Xuguang Zhu

Xuguang Zhu

Auto-generated profile, based on publicly available information

Xuguang Zhu

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SPStine M. Præstholm
Stine M. Præstholm
MSMajken S. Siersbæk
Majken S. Siersbæk
RNRonni Nielsen
Ronni Nielsen
XZXuguang Zhu
Xuguang Zhu
AHAnthony N. Hollenberg
Anthony N. Hollenberg
LGLars Grøntved
Lars Grøntved
Hormone-dependent activation of enhancers includes histone hyperacetylation and mediator recruitment. Histone hyperacetylation is mostly explained by a bimodal switch model, where histone deacetylases (HDACs) disassociate from chromatin, and histone acetyl transferases (HATs) are recruited. This model builds on decades of research on steroid receptor regulation of transcription. Yet, the general concept of the bimodal switch model has not been rigorously tested genome wide. We have used a genomics approach to study enhancer hyperacetylation by the thyroid hormone receptor (TR), described to operate as a bimodal switch. H3 acetylation, HAT and HDAC ChIP-seq analyses of livers from hypo- and hyperthyroid wildtype, TR deficient and NCOR1 disrupted mice reveal three types of thyroid hormone (T3)-regulated enhancers. One subset of enhancers is bound by HDAC3-NCOR in the absence of hormone and constitutively occupy TR and HATs irrespective of T3 levels, suggesting a poised enhancer state in absence of hormone. In presence of T3, HDAC3-NCOR1 dissociates from these enhancers leading to histone hyperacetylation, suggesting a histone acetylation rheostat function of HDACs at poised enhancers. Another subset of enhancers, not occupied by HDACs, is hyperacetylated in a T3-dependent manner, where TR is recruited to chromatin together with HATs. Lastly, a subset of enhancers, is not occupied directly by TR yet require TR for histone hyperacetylation. This indirect enhancer activation involves co-association with TR bound enhancers within super-enhancers or topological associated domains. Collectively, this demonstrates various mechanisms controlling hormone-dependent transcription and adds significant details to the otherwise simple bimodal switch model. Thyroid hormone (T3) is a central regulator of growth, thermogenesis, heart rate and metabolism. In the liver T3 binds thyroid hormone receptor beta (TRβ) controlling expression of genes involved in processes such as lipid and cholesterol metabolism. The molecular mechanisms controlling TR-dependent gene regulation are centred on a bimodal switch model. In the absence of T3 co-repressors bind TR reducing gene expression. When hormone binds TR, co-repressors dissociate, and co-activators are recruited inducing gene expression. This model predominates the current understanding of T3-regulated gene expression. However, only a few studies have tested this model by genome-wide approaches. We have quantified Histone3 acetylation genome-wide in the liver of hypo- and hyperthyroid mice and identified gene regulatory regions regulated by T3. Probing TR and co-regulators at these regulatory regions, and analysing Histone3 acetylation in mouse models for disrupted co-repressor and TR activity, reveal additional insights to the mechanisms regulating T3-dependent gene expression. We suggest a revision of the prevailing bimodal switch model which helps understanding T3-regulated gene expression in tissues such as liver. We hope that this study, together with future studies, will add new perspectives on nuclear receptor-mediated transcriptional regulation to reveal general principles.

27 August 2024 in Endocrinology
Verified
Journal Article
Open access
PDF file
XZXuguang Zhu
Xuguang Zhu
SCSheue-Yann Cheng
Sheue-Yann Cheng
Accumulated research has revealed the multifaceted roles of thyroid hormone receptors (TRs) as potent tumor suppressors across various cancer types. This review explores the intricate mechanisms underlying TR-mediated tumor suppression, drawing insights from preclinical mouse models and cancer biology. This review examines the tumor-suppressive functions of TRs, particularly TRβ, in various cancers using preclinical models, revealing their ability to inhibit tumor initiation, progression, and metastasis. Molecular mechanisms underlying TR-mediated tumor suppression are discussed, including interactions with oncogenic signaling pathways like PI3K-AKT, JAK-STAT, and transforming growth factor β. Additionally, this paper examines TRs’ effect on cancer stem cell activity and differentiation, showcasing their modulation of key cellular processes associated with tumor progression and therapeutic resistance. Insights from preclinical studies underscore the therapeutic potential of targeting TRs to impede cancer stemness and promote cancer cell differentiation, paving the way for precision medicine in cancer treatment and emphasizing the potential of TR-targeted therapies as promising approaches for treating cancers and improving patient outcomes.

7 March 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
WDWoo Kyung Lee Doolittle
Woo Kyung Lee Doolittle
XZXuguang Zhu
Xuguang Zhu
SPsunmi park
sunmi park
YZYuelin Jack Zhu
Yuelin Jack Zhu
LZLi Zhao
Li Zhao
SCSheue-Yann Cheng
Sheue-Yann Cheng

26 August 2023 in Oncogene
Verified
Journal Article
Closed access
PDF file
EHEunmi Hwang
Eunmi Hwang
WDWoo Kyung Lee Doolittle
Woo Kyung Lee Doolittle
YZYuelin Jack Zhu
Yuelin Jack Zhu
XZXuguang Zhu
Xuguang Zhu
LZLi Zhao
Li Zhao
SCSheue-Yann Cheng
Sheue-Yann Cheng

17 July 2024 in Oncogene
Verified
Journal Article
Open access
PDF file
WDWoo Kyung Lee Doolittle
Woo Kyung Lee Doolittle
XZXuguang Zhu
Xuguang Zhu
SPsunmi park
sunmi park
YZYuelin Jack Zhu
Yuelin Jack Zhu
LZLi Zhao
Li Zhao
SCSheue-Yann Cheng
Sheue-Yann Cheng